Literature DB >> 8699165

Identification of antigenic regions in the GB hepatitis viruses GBV-A, GBV-B, and GBV-C.

T J Pilot-Matias1, A S Muerhoff, J N Simons, T P Leary, S L Buijk, M L Chalmers, J C Erker, G J Dawson, S M Desai, I K Mushahwar.   

Abstract

The genomes of two novel members of the Flaviviridae associated with GB agent hepatitis (GB viruses A and B) were cloned and sequenced recently. The genome of a third novel virus (GB virus C), related to but distinct from GB viruses A and B, has also been identified and characterized. Overlapping clones encompassing the large open reading frames of these three viruses have been expressed in E. coli as CTP:CMP-3-deoxy-D-manno-octulosonate cytidylyltransferase (CKS) fusion proteins. Bacterial lysates were subjected to Western blot analyses using sera from GB agent-infected tamarins and human sera from various individuals with or "at risk" for non-A, non-B, non-C, non-D, non-E hepatitis. Antigenic regions were identified in the putative NS3, NS4, and NS5 proteins from all three viruses. An antigenic region was also identified in the putative core protein of GB virus B. Many of the clones identified originally as encoding antigenic proteins were quite large. To map these regions more narrowly, smaller overlapping clones were generated by polymerase chain reaction (PCR), expressed as recombinant CKS fusion proteins and tested by Western blot. Additionally, a lambda gt11 expression library was generated from infectious tamarin sera and immunoscreened. These studies have identified at least three epitopes in GB virus A, five epitopes in GB virus B and four epitopes in GB virus C.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699165     DOI: 10.1002/(SICI)1096-9071(199604)48:4<329::AID-JMV6>3.0.CO;2-9

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  Immunogenicity of HGV NS5 protein expressed from Sf9 insect cells.

Authors:  H Ren; F L Zhu; S Y Zhu; Y Song; Z T Qi
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

2.  Development of a primary tamarin hepatocyte culture system for GB virus-B: a surrogate model for hepatitis C virus.

Authors:  B Beames; D Chavez; B Guerra; L Notvall; K M Brasky; R E Lanford
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  GB virus B and hepatitis C virus NS3 serine proteases share substrate specificity.

Authors:  E Scarselli; A Urbani; A Sbardellati; L Tomei; R De Francesco; C Traboni
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

4.  Investigation of saliva, faeces, urine or semen samples for the presence of GBV-C RNA.

Authors:  Q R Eugenia; Q R Ana; M Carmen
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

5.  Identification of a novel sequence at the 3' end of the GB virus B genome.

Authors:  A Sbardellati; E Scarselli; L Tomei; A S Kekulé; C Traboni
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

6.  Diversity of hepatitis G virus within a single infected individual.

Authors:  L Shao; H Shinzawa; X Zhang; D B Smith; H Watanabe; H Mitsuhashi; K Saito; T Saito; H Togashi; T Takahashi
Journal:  Virus Genes       Date:  2000-10       Impact factor: 2.332

Review 7.  Human Pegivirus Type 1: A Common Human Virus That Is Beneficial in Immune-Mediated Disease?

Authors:  Jack T Stapleton
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

8.  Rapid assay for simultaneous detection and differentiation of immunoglobulin G antibodies to human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2.

Authors:  A S Vallari; R K Hickman; J R Hackett; C A Brennan; V A Varitek; S G Devare
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

Review 9.  The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae.

Authors:  Jack T Stapleton; Steven Foung; A Scott Muerhoff; Jens Bukh; Peter Simmonds
Journal:  J Gen Virol       Date:  2010-11-17       Impact factor: 3.891

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.